E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma. |
|
E.1.1.1 | Medical condition in easily understood language |
Acromegaly is a hormonal disorder that results from too much growth hormone (GH) in the body. Most cases the overproduction of GH is due to a benign tumor of the pituitary gland called an adenoma. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10000599 |
E.1.2 | Term | Acromegaly |
E.1.2 | System Organ Class | 10014698 - Endocrine disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To evaluate the efficacy of ISIS 766720 subcutaneous injection on serum insulin-like growth factor 1 (IGF-1) vs. placebo as an add-on therapy to long acting somatostatin receptor ligands (SRL) octreotide or lanreotide.
- To evaluate the safety and tolerability of ISIS 766720 subcutaneous injection vs. placebo on add-on therapy of SRL. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of ISIS 766720 to normalize serum IGF-1 levels. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements
2. Males or females with documented diagnosis of Acromegaly*. Aged 18 to 75 years old (inclusive) at the time of informed consent
* Defined as a previous diagnosis of GH-secreting adenoma by surgical pathology; or the presence of a pituitary adenoma on magnetic resonance imaging (MRI) and serum IGF-1 levels above the upper limit of normal for age and sex at time of diagnosis (serum IGF-1 level and MRI at diagnosis will be collected in the CRF)
3. Patients must be on stable maximum or maximally tolerated dose of SRL (lanreotide Autogel or octreotide LAR, per treating physician judgment) every 28 days for a minimum of 3 months prior to screening and will be required to continue their stable dose of SRL throughout the study. In accordance with US approved prescribing information, the maximal dose recommended per the package insert for lanreotide Autogel is 120 mg every 28 days and for octreotide LAR is 40 mg every 28 days (the reason for the maximally tolerated dose of SRL will be collected in the CRF). SRL dose should not exceed the maximum dose as approved in the local region (as indicated in the SRL label). Prior use of other medications for treating acromegaly (pasireotide, dopamine agonist or pegvisomant) is allowed but not within 6 weeks of screening
4. At Screening, serum IGF-1 (performed at central lab) between 1.3 to 5 x ULN, inclusive, adjusted for age and sex
5. Females must be non-pregnant and non-lactating, and either
a. surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy)
b. post-menopausal (defined as 12 months of spontaneous amenorrhea in females
> 55 years of age or, in females ≤ 55 years, 12 months of spontaneous amenorrhea without an alternative medical cause and FSH levels in the postmenopausal range for the laboratory involved)
c. abstinent or
d. Women of childbearing potential (WOCBP) should agree to taking all precaution to avoid pregnancy during the trial period (including Post-Treatment), including agreeing to receive pregnancy testing before each monthly dose, using 1 highly effective method of birth control (Section 6.3.1) from the time of signing the informed consent form until 14 weeks after the last dose of Study Drug administration
Males must be surgically sterile, abstinent or, if engaged in sexual relations with a female of child-bearing potential, the patient or the patient’s non-pregnant female partner must be using 1 highly effective contraceptive method (refer to Section 6.3.1) from the time of signing the informed consent form until 14 weeks after the last dose of Study Drug.
6. Willing to refrain from strenuous exercise/activity (for example heavy lifting, weight training, intense aerobics classes etc.) for at least 24 hours prior to study visits
7. Willing to refrain from alcohol or tobacco use for 8 hours prior to study visits
|
|
E.4 | Principal exclusion criteria |
1. Clinically-significant abnormalities in medical history (e.g., previous acute coronary syndrome within 6 months of screening, major non-pituitary surgery within 3 months of screening) or from screening physical examination
2. Patients who received surgery for pituitary adenoma within the last 6 months before the trial, and/or planning to receive surgery during the trial
3. Patients who received radiotherapy for pituitary adenoma within the last 3 years before the trial, and/or planning to receive radiotherapy during the trial
4. Patients with a pituitary tumor that, per Investigator judgment, is worsening (e.g., either growing, or at risk of compressing or abutting the optic chiasm or other vital structures) as assessed by pituitary/sellar MRI protocol at Screening or within 6 months of screening
5. Evidence of decompensated cardiac function per medical judgement and/or NYHA class 3 or 4
6. Clinical evidence of symptomatic hyperprolactinemia that would necessitate treatment
7. Symptomatic cholelithiasis, and/or choledocholithiasis
8. Have a diagnosis of Gilbert’s disease
9. Patients with history of hypoglycemia unawareness (who have had > 3 severe episodes in the past 6 months) or documented reactive hypoglycemia
10. Screening laboratory results as follows, or any other clinically-significant abnormalities in screening laboratory values that would render a patient unsuitable for inclusion. (abnormalities may be retested for eligibility purposes)
a. Urine protein/creatinine (P/C) ratio ≥ 500 mg/g. In the event of P/C ratio above this threshold eligibility may be confirmed by a quantitative total urine protein measurement of < 1000 mg/24 hr
b. Positive test (including trace) for blood on urinalysis. In the event of a positive test eligibility may be confirmed with urine microscopy showing < 5 red blood cells per high power field
c. ALT or AST > 1.2 x ULN, bilirubin > ULN; alkaline phosphatase (ALP) > 3 x ULN
d. eGFR < 45 mL/min/1.73m2 as determined by the Chronic Kidney Disease-Epidemiological Collaboration (CKD-EPI) equation for creatinine clearance OR serum creatinine > 1.8 mg/dL in males and > 1.5 mg/dL in females
e. Platelet count < LLN
f. Abnormal thyroid function tests must be approved by the Sponsor Medical Monitor
g. HbA1c > 10%
h. Morning (prior to 9 AM) blood cortisol < 10 mcg/dL (280 nmol/L)
11. Active infection requiring systemic antiviral or antimicrobial therapy that will not be completed prior to Study Day 1
12. Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
13. Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B
14. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, follicular Stage 1 or papillary thyroid cancer that has been successfully treated; patients with a history of other malignancies that have been treated with curative intent and which have no recurrence within 5 years may also be eligible if approved by the Sponsor Medical Monitor
15. Treatment with another investigational drug, biological agent, or device within 1 month of screening, or 5 half-lives of investigational agent, whichever is longer
16. Treatment with any non- ION- or ISIS-oligonucleotide (including siRNA) at any time or prior treatment with an ION- or ISIS-oligonucleotide within 9 months of screening. Patients that have previously received only a single-dose of an ION- or ISIS oligonucleotide as part of a clinical study may be included as long as a duration ≥ 4 month has elapsed since dosing
17. History of bleeding diathesis or coagulopathy
18. Recent history of, or current drug or alcohol abuse that could affect study compliance per Investigator judgment
19. Patients may not have insulin, chronic systemic use of glucocorticoids, weight loss medications or participate in weight loss programs within 2 months before randomization and during study participation
20. Patients on anti-diabetes medications must be on a stable dose and regimen for ≥ 3 months prior to screen and throughout the trial. Patients taking GLP-1 agonists can be allowed with prior consultation with the Sponsor Medical Monitor
21. Patients on estrogen containing medications must be on a stable dose and regimen for
≥ 3 months prior to screening and throughout the trial
22. Use of oral anticoagulants, unless the dose has been stable for 4 weeks prior to the first dose of Study Drug and regular clinical monitoring is performed during the trial
23. Blood donation of 50 to 499 mL within 30 days of screening or of > 499 mL within 60 days of screening and during the trial
24. Have any other conditions, which, in the opinion of the Investigator and Sponsor would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the Study
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the percent change in IGF-1 from Baseline to 28 Days after last dose (PTWk5 Visit).
The safety endpoints include:
•Adverse events
•Vital signs and weight and calculated BMI
•Physical examination
•Clinical laboratory tests
•ECG
•Use of concomitant medication |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Comparison of percent change from Baseline to PTWk5 (28 days after last dose) in serum IGF-1 between ISIS 766720 80 mg group and pooled placebo group in the Per Protocol Set.
Safety Analyses:
The treatment-emergent adverse events (TEAEs) and SAEs analysed the whole duration of the study.
Laboratory tests including chemistry panel, CBC with differential, coagulation panel, complement etc., will be summarized by study visits for each treatment group. |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints include:
• Proportion of patients achieve normalized IGF-1 levels to within 1.2 times of gender and aged limits at 28 days after last dose (PTWk5 Visit)
• Proportion patients achieve normalized IGF-1 levels to within 1.0 times of gender and aged limits at 28 days after last dose (PTWk5 Visit)
• Change from Baseline in serum IGF-1 over time
• Percent change from Baseline in serum IGF-1 over time
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Measure of IGF-1 level at 28 days after last dose (PTWk5 Visit)
• Serum IGF-1 level change measured throughout the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Czech Republic |
Hungary |
Lithuania |
Poland |
Romania |
Russian Federation |
Serbia |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |